Allianz Asset Management GmbH Boosts Stock Position in Integra LifeSciences Holdings Corporation $IART

Allianz Asset Management GmbH grew its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 53.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 229,904 shares of the life sciences company’s stock after purchasing an additional 80,290 shares during the period. Allianz Asset Management GmbH’s holdings in Integra LifeSciences were worth $2,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in IART. CWM LLC grew its position in shares of Integra LifeSciences by 32.6% in the second quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock valued at $108,000 after purchasing an additional 2,170 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Integra LifeSciences by 6,017.6% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock valued at $124,000 after purchasing an additional 9,929 shares in the last quarter. Compass Financial Group INC SD purchased a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $172,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Integra LifeSciences by 16.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 13,352 shares of the life sciences company’s stock valued at $180,000 after purchasing an additional 1,927 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Integra LifeSciences in the first quarter valued at approximately $223,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Up 1.5%

NASDAQ:IART opened at $16.12 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The stock’s fifty day moving average is $14.72 and its two-hundred day moving average is $13.99. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -2.47 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company had revenue of $415.61 million for the quarter, compared to analysts’ expectations of $395.06 million. During the same period in the prior year, the firm earned $0.63 earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on IART shares. Citigroup reiterated a “sell” rating and issued a $12.00 price objective (up from $10.00) on shares of Integra LifeSciences in a report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Finally, Truist Financial set a $15.00 price objective on Integra LifeSciences and gave the company a “hold” rating in a report on Wednesday, October 15th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Reduce” and a consensus target price of $16.17.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.